Switch theme
Sign up to access all valuation multiples
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
1928
9.4K+
LTM Revenue $7.2B
LTM EBITDA $1.9B
$35.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
UCB has a last 12-month revenue (LTM) of $7.2B and a last 12-month EBITDA of $1.9B.
In the most recent fiscal year, UCB achieved revenue of $6.9B and an EBITDA of $2.2B.
UCB expects next 12-month revenue of XXX and NTM EBITDA of XXX
See UCB valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2B | XXX | $6.9B | XXX | XXX | XXX |
| Gross Profit | $5.2B | XXX | $4.9B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $1.9B | XXX | $2.2B | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $1.5B | XXX | $970M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, UCB's stock price is EUR 160 (or $180).
UCB has current market cap of EUR 30.4B (or $34.1B), and EV of EUR 31.7B (or $35.6B).
See UCB trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.6B | $34.1B | XXX | XXX | XXX | XXX | $6.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, UCB has market cap of $34.1B and EV of $35.6B.
UCB's trades at 5.1x EV/Revenue multiple, and 16.1x EV/EBITDA.
Equity research analysts estimate UCB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
UCB has a P/E ratio of 27.9x.
See valuation multiples for UCB and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34.1B | XXX | $34.1B | XXX | XXX | XXX |
| EV (current) | $35.6B | XXX | $35.6B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 18.4x | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBIT | 23.3x | XXX | 36.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.9x | XXX | 28.5x | XXX | XXX | XXX |
| EV/FCF | 26.4x | XXX | 34.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUCB's last 12 month revenue growth is 12%
UCB's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
UCB's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
UCB's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for UCB and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
UCB acquired XXX companies to date.
Last acquisition by UCB was XXXXXXXX, XXXXX XXXXX XXXXXX . UCB acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was UCB founded? | UCB was founded in 1928. |
| Where is UCB headquartered? | UCB is headquartered in Belgium. |
| How many employees does UCB have? | As of today, UCB has 9.4K+ employees. |
| Who is the CEO of UCB? | UCB's CEO is Mr. Jean-Christophe Tellier. |
| Is UCB publicy listed? | Yes, UCB is a public company listed on BRU. |
| What is the stock symbol of UCB? | UCB trades under UCB ticker. |
| When did UCB go public? | UCB went public in 1988. |
| Who are competitors of UCB? | Similar companies to UCB include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of UCB? | UCB's current market cap is $34.1B |
| What is the current revenue of UCB? | UCB's last 12 months revenue is $7.2B. |
| What is the current revenue growth of UCB? | UCB revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of UCB? | Current revenue multiple of UCB is 4.9x. |
| Is UCB profitable? | Yes, UCB is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of UCB? | UCB's last 12 months EBITDA is $1.9B. |
| What is UCB's EBITDA margin? | UCB's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of UCB? | Current EBITDA multiple of UCB is 18.4x. |
| What is the current FCF of UCB? | UCB's last 12 months FCF is $1.3B. |
| What is UCB's FCF margin? | UCB's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of UCB? | Current FCF multiple of UCB is 26.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
